UP!
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: NVAX S&P 500 Component |
| Industry | Biotechnology |
| Founded | 1987 (1987) |
| Headquarters | Gaithersburg, Maryland, U.S. |
|
Area served
|
Worldwide |
| Products | Vaccines |
|
Number of employees
|
ca 375 |
| Website | www |
Coordinates: 39°08′14″N 77°13′33″W / 39.1371167°N 77.2258056°W / 39.1371167; -77.2258056
Novavax, Inc. is a clinical-stage vaccine company headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is a public company that trades under the symbol "NVAX".
In June 2013, Novavax acquired the Matrix-M adjuvant platform with the purchase of Swedish company Isconova AB and renamed it Novavax AB.
In 2015 the company received an $89 million grant from the Bill & Melinda Gates Foundation to support the development of a vaccine against human respiratory syncytial virus for infants via maternal immunization.
In March 2015 the company completed a Phase I trial for its Ebola vaccine candidate.
In September 2016 the company announced that a Phase III trial of its RSV vaccine had failed to meet its endpoints, which caused its share price to fall from $8.34 to $1.40 and led the company to lay off 30% of its employees.
As of November 2016 its RSV F vaccine candidate was in three clinical trials.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-02 | Future report Set alerts | |
| Q2 2022 | 2022-08-08 | -6.53 | -6.53 |
| Q1 2022 | 2022-05-09 | 2.56 | 2.56 |
| Q4 2021 | 2022-02-28 | -11.18 | -11.18 |
| Q3 2021 | 2021-11-04 | -4.31 | -4.31 |
| Q2 2021 | 2021-08-05 | -4.75 | -4.75 |
| Q1 2021 | 2021-05-10 | -3.05 | -3.05 |
| Q4 2020 | 2021-03-01 | -2.70 | -2.70 |
| Q3 2020 | 2020-11-09 | -3.21 | -3.21 |
| Q2 2020 | 2020-08-10 | -0.30 | -0.30 |
| 2016-06-29 | Reiterated Rating | Piper Jaffray | Overweight | $14.00 |
| 2016-06-29 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $14.00 |
| 2016-06-02 | Reiterated Rating | Wedbush | Outperform | $14.00 |
| 2016-05-25 | Reiterated Rating | Wedbush | Outperform | $14.00 |
| 2016-05-02 | Reiterated Rating | Chardan Capital | Neutral | |
| 2016-04-04 | Initiated Coverage | Chardan Capital | Neutral | $5.75 |
| 2016-03-03 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $14.00 to $12.00 |
| 2016-03-01 | Reiterated Rating | FBR & Co. | Outperform | $17.00 |
| 2016-03-01 | Reiterated Rating | FBR & Co | Outperform | $17.00 |
| 2016-02-29 | Reiterated Rating | Wedbush | Outperform | $14.00 |
| 2016-02-16 | Reiterated Rating | Wedbush | Outperform | $14.00 |
| 2015-12-15 | Reiterated Rating | Wedbush | Outperform | $14.00 |
| 2015-10-30 | Reiterated Rating | FBR & Co. | Outperform | |
| 2015-10-02 | Lower Price Target | Citigroup Inc. | Buy | $18.00 to $16.00 |
| 2015-09-30 | Reiterated Rating | FBR & Co. | Outperform | $17.00 |
| 2015-09-29 | Reiterated Rating | Piper Jaffray | Buy | |
| 2015-08-11 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $10.00 to $14.00 |
| 2015-08-11 | Reiterated Rating | Piper Jaffray | Overweight | $15.00 to $17.00 |
| 2015-08-03 | Initiated Coverage | Guggenheim | Market Perform | $17.00 |
| 2015-08-02 | Reiterated Rating | Ladenburg Thalmann | Buy | |
| 2015-07-21 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
| 2015-07-09 | Boost Price Target | Citigroup Inc. | Buy | $10.00 to $18.00 |
| 2015-06-09 | Initiated Coverage | Guggenheim | Buy | $11.00 |
| 2015-04-07 | Reiterated Rating | Janney Montgomery Scott | $12.00 | |
| 2015-03-27 | Reiterated Rating | Citigroup Inc. | Buy | $10.00 |
| 2015-02-12 | Initiated Coverage | GMP Securities | Positive | |
| 2015-01-09 | Initiated Coverage | Janney Montgomery Scott | Buy | $11.00 |
| 2014-10-07 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $7.00 |
| 2014-09-24 | Boost Price Target | Piper Jaffray | Overweight | $9.00 to $10.50 |
| 2014-09-18 | Initiated Coverage | Wedbush | Outperform | $10.00 |
| 2014-08-13 | Initiated Coverage | Citigroup Inc. | Buy | $9.00 |
| 2014-08-07 | Lower Price Target | FBR & Co. | Outperform | $11.00 to $10.00 |
| 2014-03-11 | Boost Price Target | Ladenburg Thalmann | Buy | $4.00 to $10.00 |
| 2013-12-16 | Boost Price Target | Wedbush | Positive | $12.00 |
| 2013-11-18 | Reiterated Rating | FBR & Co. | Outperform to Positive | $11.00 |
| 2013-10-30 | Initiated Coverage | FBR & Co. | Outperform | $11.00 |
| 2013-09-25 | Reiterated | MLV & Co | Buy | $8.50 to $9.50 |
| 2013-09-25 | Boost Price Target | MLV & Co. | Buy | $8.50 to $9.50 |
| 2011-03-15 | Initiated | Wedbush | Outperform | $6 |
| 2010-06-15 | Initiated | Dawson James | Buy | $4.50 |
| 2010-03-15 | Initiated | Roth Capital | Buy | $5 |
| 2009-12-03 | Initiated | Global Hunter Securities | Buy | $7.25 |
| 2009-12-01 | Initiated | Piper Jaffray | Overweight | $4.50 |
| 2009-11-05 | Initiated | Merriman | Buy | $7 |
| 2009-09-02 | Downgrade | Oppenheimer | Outperform to Perform | |
| 2009-04-02 | Initiated | Rodman & Renshaw | Mkt Perform | $4 |
| 2007-12-11 | Reiterated | RBC Capital Mkts | Sector Perform | $3 to $4 |
| 2007-10-31 | Upgrade | Oppenheimer | Neutral to Buy | $6 |
| 2016-06-29 | Reiterated Rating | Piper Jaffray | Overweight | $14.00 |
| 2016-06-29 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $14.00 |
| 2016-06-02 | Reiterated Rating | Wedbush | Outperform | $14.00 |
| 2016-05-25 | Reiterated Rating | Wedbush | Outperform | $14.00 |
| 2016-05-02 | Reiterated Rating | Chardan Capital | Neutral |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In NVAX 178 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Fund Advisors | 12.07M |
| BlackRock Institutional Trust Company, N.A. | 7.61M |
| Vanguard Group, Inc | 7.50M |
| BlackRock Inc. | 4.33M |
| STATE STREET CORP | 3.66M |
| CITADEL ADVISORS LLC | 2.84M |
| CITIGROUP INC | 2.53M |
| BANK OF AMERICA CORP /DE/ | 1.40M |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.33M |
| TIAA CREF INVESTMENT MANAGEMENT LLC | 1.27M |
| COATUE MANAGEMENT LLC | 1.24M |
| MORGAN STANLEY | 1.09M |
| GEODE CAPITAL MANAGEMENT, LLC | 1.04M |
| BlackRock Investment Management, LLC | 1.01M |
| CAPITAL FUND MANAGEMENT S.A. | 0.95M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Cadila Pharmaceuticals Ltd | 3.98% (9500000) | NVAX / |
| Modi Rajiv I. | 1.05% (2500000) | NVAX / |
| DOUGLAS RICHARD | 0.23% (550000) | ALDX / NVAX / |
| EVANS GARY C | 0.14% (321979) | GRH / MHR / NVAX / |
| MCMANUS MICHAEL A JR | 0.12% (277590) | EML / MSON / NVAX / SHLM / |
| Erck Stanley C | 0.10% (228279) | BCRX / NVAX / |
| Hahn Timothy Jon SVP, Manufacturing & PD | 0.05% (110485) | NVAX / |
| Trizzino John Snr. VP, Int & Govt Alliances | 0.04% (88965) | NVAX / |
| Wilson Russell P SVP, Business Development | 0.03% (64939) | NVAX / |
| PHILLIPS BARCLAY A | 0.02% (38669) | NVAX / |
| Glenn Gregory M Chief Scientific Officer | 0.01% (27211) | NVAX / |
| DRISCOLL FREDERICK W VP, CFO & Treasurer | 0.01% (20000) | FLXN / MEIP / NVAX / OXGN / |
UM